Aprea Therapeutics (NASDAQ:APRE) Issues Earnings Results

Aprea Therapeutics (NASDAQ:APRE) released its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.11, FiscalAI reports. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 56.85%.

Aprea Therapeutics Stock Down 1.8%

APRE opened at $0.67 on Friday. The stock’s fifty day moving average is $0.71 and its two-hundred day moving average is $0.77. The company has a market capitalization of $8.31 million, a P/E ratio of -0.62 and a beta of 1.52. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $1.79.

Wall Street Analyst Weigh In

APRE has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Friday, July 17th. Wedbush cut their price objective on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Oppenheimer started coverage on Aprea Therapeutics in a report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.07.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC bought a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.67% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission. 34.19% of the stock is owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.